MiscellaneousAbivax Publishes 2025 Financial Calendar 28.01.2025 / 08:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax Publishes 2025 Financial Calendar PARIS, ...

Denver Location Boasts Private Infusion Suites for Addressing Patients’ Specialty Therapy Needs Soleo Health, an innovative ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as colorectal cancer, in the five years.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use by the NHS. The new ...

Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

“These results are very promising, and we fully endorse the further development of this exciting new oral compound both in ulcerative colitis as well as in other inflammatory diseases including ...